Tech Company Financing Transactions
Seres Therapeutics Funding Round
Seres Therapeutics closed a $48 million financing round on 12/2/2014. Investors included private investors.
Transaction Overview
Company Name
Announced On
12/2/2014
Transaction Type
Venture Equity
Amount
$47,999,977
Round
Undisclosed
Investors
Proceeds Purpose
Proceeds purposes were not disclosed. SEC regulatory filing. Contact technology company for investment details, if applicable. Not an offer or solicitation for sale of securities.
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
200 Sidney St.
Cambridge, MA 02139
USA
Cambridge, MA 02139
USA
Phone
Website
Email Address
Overview
Seres Therapeutics (NASDAQ: MCRB) is creating a new class of medicines to treat diseases resulting from functional deficiencies in the microbiome, a condition known as dysbiosis.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Roger Pomerantz
Chief Financial Officer
Eric Shaff
Chief Medical Officer
Michele Trucksis
Chief Scientific Officer
David Cook
Chief Technical Officer
John Aunins
VP - Bus. Development
Henry Rath
VP - General Counsel
Thomas DesRosier
VP - Operations
Carol Cullinan
VP - R & D
Matthew Henn
VP - Regulatory Affairs
Barbara McGovern
Browse more venture capital transactions:
Prev: 12/2/2014: The Rounds venture capital transaction
Next: 12/2/2014: OpenLabel venture capital transaction
Share this article
About Our Venture Capital Transactions Database
Our team works diligently to report on all VC transactions involving tech companies. VC investment data records reported here are sourced from company press releases and news coverage. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs